Avita's ReCell meets in pivotal trial for third-degree burns

Avita Medical Ltd. (ASX:AVH; OTCQX:AVMXY) said ReCell met the co-primary endpoints in a pivotal trial to treat deep full-thickness (third-degree) burns. ReCell is a point-of-care autologous cell harvesting device that creates a regenerative epithelial suspension (RES) to regenerate skin.

On the first co-primary endpoint, the patient donor skin requirement for harvest was 32% lower with ReCell compared with standard meshed autograft (p<0.001). On the second co-primary endpoint, ReCell was non-inferior to standard meshed autograft in the proportion of burn sites that achieved complete wound closure at week 8 (92% vs. 85%)...